Arbutus Biopharma is rated Buy following a $179.1 million settlement with Moderna and a $46 million share buyback aimed at increasing shareholder value. The company’s key asset, Imdusiran, is an RNAi drug targeting chronic hepatitis B with potential peak annual revenues between $1.59 billion and $2.39 billion if successful. Its current share price slightly exceeds the risk-adjusted fair value, with upside dependent on positive late-stage trial results. Risks include reliance on a single late-stage drug and market speculation on future litigation outcomes.
Arbutus Biopharma is the subject of this update, providing context with Pluang's Health sector data. For readers following Health stocks, of 128 priced US Health-sector stocks tradable on Pluang, 20 rose and 107 fell today. Notable movers include ABCL at USD 12.03 with a 1-day change of -6.24%, IMVT at USD 30.08 down 6.12%, and DFTX at USD 32.95 down 6.10%, as of Oct 08, 2026 23:11 WIB.
Pacira BioSciences was downgraded from Buy to Hold by Needham following Viatris's announcement to acquire the company for $36.50 per share, valuing it at about $1.65 billion. The deal is expected to close by late 2026 and will enhance Viatris's portf...
Enova International, a financial services company specializing in machine learning-driven lending, announced it will release its third quarter 2026 financial results after market close on October 22, 2026. The company will hold a conference call the ...
Carrier Global Corporation, a leader in climate and energy solutions, will announce its third quarter 2026 earnings on October 29, 2026. The company will host a webcast and conference call at 7:30 a.m. ET to discuss the results. Investors can access ...
SVRN, Inc. has acquired FastNEAR, a key provider of RPC infrastructure for NEAR Protocol, making FastNEAR a wholly owned subsidiary. This acquisition strengthens SVRN's involvement in the NEAR ecosystem by adding critical network services used by dev...
Brookdale Senior Living Inc. reported a significant increase in its occupancy rate for the third quarter of 2026, reaching 83.1%, which is a 130 basis point rise compared to the previous year. Additionally, the company saw a 70 basis point sequential...
